These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 33963876)

  • 21. L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
    Ando K; Inoue T; Itoh T
    Pharmacol Biochem Behav; 2014 Dec; 127():62-9. PubMed ID: 25449794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
    Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of mGlu
    Frouni I; Hamadjida A; Kwan C; Bédard D; Nafade V; Gaudette F; Nuara SG; Gourdon JC; Beaudry F; Huot P
    Neuropharmacology; 2019 Nov; 158():107725. PubMed ID: 31351976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The highly selective 5-HT
    Hamadjida A; Nuara SG; Bédard D; Gaudette F; Beaudry F; Gourdon JC; Huot P
    Neuropharmacology; 2018 Sep; 139():61-67. PubMed ID: 29969592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined 5-HT
    Kwan C; Frouni I; Nuara SG; Belliveau S; Kang W; Hamadjida A; Bédard D; Beaudry F; Panisset M; Gourdon JC; Huot P
    Neuropharmacology; 2021 Mar; 186():108465. PubMed ID: 33485945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
    Maratos EC; Jackson MJ; Pearce RK; Cannizzaro C; Jenner P
    Exp Neurol; 2003 Jan; 179(1):90-102. PubMed ID: 12504871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gypenosides ameliorate memory deficits in MPTP-lesioned mouse model of Parkinson's disease treated with L-DOPA.
    Zhao TT; Kim KS; Shin KS; Park HJ; Kim HJ; Lee KE; Lee MK
    BMC Complement Altern Med; 2017 Sep; 17(1):449. PubMed ID: 28877690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
    Huot P; Johnston TH; Koprich JB; Fox SH; Brotchie JM
    Neuropharmacology; 2012 Oct; 63(5):829-36. PubMed ID: 22722022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
    Fox SH; Henry B; Hill M; Crossman A; Brotchie J
    Mov Disord; 2002 Nov; 17(6):1180-7. PubMed ID: 12465055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE; Fox SH; Henry B; Hill MP; Peggs D; McGuire S; Maneuf Y; Hille C; Brotchie JM; Crossman AR
    Exp Neurol; 2000 Sep; 165(1):136-42. PubMed ID: 10964492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).
    Maratos EC; Jackson MJ; Pearce RK; Jenner P
    Mov Disord; 2001 Jul; 16(4):631-41. PubMed ID: 11481686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.
    Henry B; Fox SH; Peggs D; Crossman AR; Brotchie JM
    Mov Disord; 1999 Sep; 14(5):744-53. PubMed ID: 10495035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset.
    Huot P; Johnston TH; Gandy MN; Reyes MG; Fox SH; Piggott MJ; Brotchie JM
    PLoS One; 2012; 7(9):e45587. PubMed ID: 23029119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Johnston TH; Fox SH; McIldowie MJ; Piggott MJ; Brotchie JM
    J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of (-)-sesamin on motor and memory deficits in an MPTP-lesioned mouse model of Parkinson's disease treated with l-DOPA.
    Zhao TT; Shin KS; Kim KS; Park HJ; Kim HJ; Lee KE; Lee MK
    Neuroscience; 2016 Dec; 339():644-654. PubMed ID: 27789382
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study.
    Johnston TH; Huot P; Damude S; Fox SH; Jones SW; Rusche JR; Brotchie JM
    Parkinsonism Relat Disord; 2013 Feb; 19(2):260-4. PubMed ID: 22901956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Positive allosteric mGluR
    Kang W; Frouni I; Bédard D; Kwan C; Hamadjida A; Nuara SG; Gourdon JC; Huot P
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Nov; 397(11):8917-8924. PubMed ID: 38861009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE; Ravenscroft P; McGuire S; Crossman AR; Menniti FS; Brotchie JM
    Exp Neurol; 2004 Aug; 188(2):471-9. PubMed ID: 15246846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.
    Kuoppamäki M; Al-Barghouthy G; Jackson M; Smith L; Zeng BY; Quinn N; Jenner P
    Mov Disord; 2002 Nov; 17(6):1312-7. PubMed ID: 12465074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.
    Hill MP; Bezard E; McGuire SG; Crossman AR; Brotchie JM; Michel A; Grimée R; Klitgaard H
    Mov Disord; 2003 Nov; 18(11):1301-5. PubMed ID: 14639671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.